Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$0.95 and traded as high as C$1.80. Oncolytics Biotech shares last traded at C$1.73, with a volume of 245,934 shares traded.
Analyst Ratings Changes
Separately, Jones Trading cut Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a report on Friday, May 16th.
Read Our Latest Stock Report on Oncolytics Biotech
Oncolytics Biotech Trading Down 2.8%
The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75. The firm has a market capitalization of C$133.34 million, a PE ratio of -4.82 and a beta of 1.35. The firm's 50-day simple moving average is C$0.92 and its 200-day simple moving average is C$0.95.
Insider Activity
In related news, Senior Officer Andrew P. Aromando purchased 25,500 shares of Oncolytics Biotech stock in a transaction that occurred on Tuesday, July 15th. The stock was bought at an average cost of C$1.62 per share, for a total transaction of C$41,425.92. Also, Senior Officer Thomas Heineman bought 15,000 shares of the company's stock in a transaction dated Thursday, July 17th. The shares were acquired at an average cost of C$1.74 per share, with a total value of C$26,098.50. Insiders acquired a total of 108,300 shares of company stock valued at $178,192 in the last 90 days. Company insiders own 3.82% of the company's stock.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Articles
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
